Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival

Sistiana Aiello¹, Federica Rocchetta¹, Lorena Longaretti¹, Silvia Faravelli¹, Marta Todeschini³, Linda Cassis², Francesca Pezzuto¹, Susanna Tomasoni¹, Nadia Azzollini², Marilena Mister¹, Caterina Mele¹, Sara Conti¹, Matteo Breno¹, Giuseppe Remuzzi¹,³,⁴, Marina Noris¹ & Ariela Benigni¹

We have previously shown that rat allogeneic DC, made immature by adenoviral gene transfer of the dominant negative form of IKK2, gave rise in-vitro to a unique population of CD4⁺CD25⁻ regulatory T cells (dnIKK2-Treg). These cells inhibited T cell response in-vitro, without needing cell-to-cell contact, and induced kidney allograft survival prolongation in-vivo. Deep insight into the mechanisms behind dnIKK2-Treg-induced suppression of T cell proliferation remained elusive. Here we document that dnIKK2-Treg release extracellular vesicles (EV) riched in exosomes, fully accounting for the cell-contact independent immunosuppressive activity of parent cells. DnIKK2-Treg-EV contain a unique molecular cargo of specific miRNAs and iNOS, which, once delivered into target cells, blocked cell cycle progression and induced apoptosis. DnIKK2-Treg-EV-exposed T cells were in turn converted into regulatory cells. Notably, when administered in-vivo, dnIKK2-Treg-EV prolonged kidney allograft survival. DnIKK2-Treg-derived EV could be a tool for manipulating the immune system and for discovering novel potential immunosuppressive molecules in the context of allotransplantation.

Organ transplantation is the most effective treatment for end-stage organ failure, and in recent decades immunosuppressive drugs have greatly increased graft survival in transplant patients. However, since long-lasting immunosuppression can increase the occurrence of opportunistic infections and the incidence of cancer, one major aim of transplantation research is to find new ways to induce allograft acceptance/tolerance, eliminating or reducing the use of immunomodulatory molecules.

In the past two decades, the tolerogenic/regulatory capacity of immature dendritic cells (DC) has been exploited to promote long-term allograft acceptance. Administering immature donor or donor-antigen-loaded recipient DC, by themselves or through interaction with host DC, promotes the deletion of donor-reactive T cells and increases the number of donor-specific regulatory T cells (Treg). As an alternative approach, immature DC have been used to generate Treg in-vitro. In this context, we showed that rat allogeneic DC made immature by blocking NF-κB through adenoviral gene transfer of the dominant negative form of IKK2 (dnIKK2), gave rise in-vitro to a unique population of CD4⁺CD25⁻ regulatory T cells (dnIKK2-Treg). These cells potently inhibited the T cell response in-vitro, without the need for cell-to-cell contact, and induced prolongation of kidney allograft survival in-vivo. However, deep insight into the mechanism(s) behind dnIKK2-Treg suppression of T cell proliferation remains elusive.

Several cell contact-independent mechanisms have been involved in the suppression of T cell activation by Treg, including deprivation of cytokines, such as IL-2, and the release of inhibitory factors, including IL-10, TGF-β, IL-35 and galectin-1. More recently, Treg have been shown to release extracellular vesicles (EV) and exosomes, which deliver suppressive messages into target cells, allowing cell contact-independent suppression.

¹IRCCS-Istituto di Ricerche Farmacologiche Mario Negri, Centro Ricerche Trapianti Chiara Cucci de Alessandri e Gilberto Crespi Ranica, Bergamo, Italy. ²Institut Hospital del Mar d'Investigacions Mèdiques, Barcelona, Spain. ³Unit of Nephrology and Dialysis, Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII, Bergamo, Italy. ⁴Unit of Nephrology and Dialysis, Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy. Correspondence and requests for materials should be addressed to M.N. (email: marina.noris@marionegri.it)
Figure 1. dnIKK2-Treg release extracellular vesicles riched in exosomes. (A) EV released by CFSE stained dnIKK2-Treg were CFSE+. DnIKK2-Treg were stained with CFSE, EV were prepared from conditioned medium, conjugated to latex beads and FACS-analyzed. Left dot plot: latex beads alone. Right dot plot: latex beads conjugated with dnIKK2-Treg-EV. One representative experiment of 3 is shown. (B) FACS analysis of membrane antigens on dnIKK2-Treg-EV. dnIKK2-Treg-EV were PKH26-labeled, conjugated to latex beads, stained with FITC-conjugated anti-CD11c antibody (upper panels), or AF647-conjugated anti-CD3 antibody (lower panels) and FACS-analyzed. Left dot plots: latex beads conjugated with not-stained dnIKK2-Treg-EV. Right dot plots: latex beads conjugated with PKH26-labelled and antibody-stained dnIKK2-Treg-EV. Analysis was done on gated beads, 5000 events are shown. One representative experiment of 3 is shown. (C) CD63 protein expression. CD63 in dnIKK2-Treg (left lane) or dnIKK2-Treg-EV (right lane) was analyzed by Western
inter-cellular communication. Exosomes are small membrane vesicles of endocytic origin riched in bioactive messengers (both proteins and RNAs), which can be delivered into target cells after fusing with their plasma membranes. The cargo of bioactive messengers, which dictates the effect on target cells, is strictly dependent on the cell from which vesicles derive and on its physiological status. Indeed, exosomes secreted by mature DC efficiently engage T cell activation in vitro as well as in vivo, whereas exosomes released by immature DC promote tolerogenic immune responses both in vitro and in vivo. Interestingly, a recent paper documented that naturally occurring Treg release exosomes that suppress pathogenic T helper 1 (Th1) cells in murine colitis through the transfer of microRNA (miRNA).

This study was designed to: 1) evaluate whether dhnKK2-Treg released EV; 2) investigate whether EV played a role in mediating the cell contact-independent immunoregulatory properties of dhnKK2-Treg in vitro; 3) search for the mechanism underlying their immunomodulatory effect; and 4) verify whether dhnKK2-Treg-derived EV affect graft survival in a kidney allotransplant model.

We found that dhnKK2-Treg release EV riched in exosomes (dhnKK2-Treg-EV) that account fully for the T cell regulatory activity of dhnKK2-Treg in vitro. In addition, dhnKK2-Treg-EV were capable of converting T cells into regulatory cells and prolonged kidney allograft survival in vivo. The mechanism underlying the immune-modulating capacity of dhnKK2-Treg-EV is based on their unique molecular cargo, consisting of specific miRNAs and iNOS enzyme, which, once delivered into naïve T cells, block cell cycle progression and induce apoptosis.

Results

DhnKK2-Treg release EV riched in exosomes. First we assessed the ability of dhnKK2-Treg to release EV. The majority of EV isolated from conditioned medium of CFSE-labeled dhnKK2-Treg were CFSE+ (Fig. 1A). PKH26-stained vesicles were negative for CD11c and positive for CD3 antigens (Fig. 1B), and these results confirmed that they were EV of T cell origin. The presence of CD63, as well as of Tsg101, a specific marker of vesicles of endosomal origin, and the absence of calnexin, a marker of vesicles of endoplasmic reticulum origin (Fig. 1C,D), suggested that dhnKK2-Treg-EV were mostly exosomes. Electron microscopy confirmed the nature of cup-shaped CD63+ exosomes, which measured 50–100 nm in size (Fig. 1E,F). Similarly to dhnKK2-Treg-EV, EV released from activated T cells (Tact-EV) expressed Tsg101 (Supplementary Fig. 1). Tsg101 expression was faint in EV from resting T cells (Trest-EV) indicating a low amount of vesicles of endocytic origin released from Trest (Supplementary Fig. 1). Both Tact-EV and Trest-EV were negative for calnexin (Supplementary Fig. 1).

DhnKK2-Treg-EV suppress T cell proliferation. EV were taken up by target cells, as demonstrated by the fact that more than 75% of T cells expressed PKH26 after their exposure to PKH26-stained dhnKK2-Treg-EV (Fig. 1G). To test whether, following such engagement, dhnKK2-Treg-EV were responsible for the cell-to-cell contact-independent suppressive activity of dhnKK2-Treg, naïve T cell proliferation was evaluated at the end of a 4-day MLR in the presence of dhnKK2-Treg-EV.

As shown in Fig. 2A, dhnKK2-Treg-EV potentely suppressed T cell proliferation in allogenic MLR (allo-MLR, 1:2) in a dose-dependent manner. A significant inhibition of T cell proliferation was achieved by EV from 2,000 dhnKK2-Treg but was further increased in the presence of EV from 20,000 to 200,000. EV from 2 to 200 dhnKK2-Treg did not inhibit T cell proliferation. So we elected to use EV from 20,000 dhnKK2-Treg (corresponding to approximately 40–60 ng of proteins) for further experiments. The suppressive activity was lost completely when dhnKK2-Treg-EV were disrupted by 4–5 cycles of freeze and thaw (Fig. 2A). EV released by either CD4+ activated (Tact-EV) or CD4+ resting T cells (Trest-EV) did not affect T cell proliferation (Fig. 2A). Notably, dhnKK2-Treg-EV were able to suppress even T cells stimulated by a polyclonal stimulus, such as Concanavalin A (Fig. 2B), suggesting that dhnKK2-Treg-EV exerted their suppressive activity directly on T cells and not through the inhibition of DC stimulatory capacity.

The anti-proliferative effect of dhnKK2-Treg-EV was confirmed by the CFSE dilution assay showing that CD3+ T cell proliferation was reduced by 43 ± 10% (mean ± SD, n = 3) at the end of MLR performed in the presence of EV from 20,000 dhnKK2-Treg, compared to an allo-MLR. A more detailed analysis showed that proliferation of both CD4+ and CD8+ T cells was reduced in the presence of dhnKK2-Treg-EV (Fig. 2C and Supplementary Fig. 2). The percentage of proliferation reduction was similar in the CD4+ and CD8+ T cell subsets (44 ± 13% and 41 ± 5% respectively, mean ± SD, n = 3).

DhnKK2-Treg-EV fully accounted for the suppressive effect originally described with the cells of origin, since a comparable suppressive effect was achieved either by EV from 20,000 dhnKK2-Treg or by 20,000 dhnKK2-Treg (Fig. 2D). To further confirm that dhnKK2-Treg-EV accounted for the suppressive effect, T cell
Figure 2. dnIKK2-Treg-EV suppress T cell proliferation. (A) Suppressive effect of LW dnIKK2-Treg-EV. A 4-day allogeneic MLR (Allo-MLR, $1 \times 10^6$ LW lymph-node cells + 10,000 BN mature DC) was performed +/− EV from either dnIKK2-Treg (n = 5), or activated T cells (Tact, n = 2) or resting T cells (Trest, n = 2), or disrupted (freeze/thaw) dnIKK2-Treg-EV (n = 2). Syn-MLR: $1 \times 10^6$LW lymph-node cells + 10,000 LW mature DC. Proliferation was measured by incorporation of $^3$H-Thymidine at day4 and expressed as cpm. Results are mean ± SE. *p < 0.05 vs all groups. (B) T cells were stimulated with ConA +/− dnIKK2-Treg-EV. Proliferation was measured by $^3$H-Thymidine incorporation and expressed as cpm (mean ± SD, n = 3, *p < 0.05 vs ConA). (C) A 4-day Allo-MLR was performed with (lower panels) or without (upper panels) EV from 20,000 dnIKK2-Treg. Left dot plots: double staining for CFSE and CD4. Right dot plots: double staining for CFSE and CD8. Percentages of CD4+ or CD8+ T cells that proliferated are given in upper left quadrants. One experiment of 3 is shown. (D) A 4-day Allo-MLR was performed +/− EV from 20,000 dnIKK2-Treg, or 20,000 dnIKK2-Treg, or conditioned medium from 20,000 dnIKK2-Treg (either untreated, or after 4–5 cycles of freeze and thaw, or after 100 kDa size exclusion filtering). Proliferation was measured by incorporation of $^3$H-Thymidine at day4 and expressed as cpm. (mean ± SD, n = 3, *p < 0.05 vs Allo-MLR, Allo-MLR + freezed-thawed conditioned medium, Allo-MLR + <100 kDa fraction of conditioned medium). (E) Suppressive effect of DA dnIKK2-Treg-EV. A 4-day Allo-MLR (1 × 10^6 DA lymph-node cells + 10,000 BN mature DC) was performed +/− EV from DA dnIKK2-Treg. Proliferation was measured by incorporation of $^3$H-Thymidine at day4 and expressed as cpm. (mean ± SD, n = 3, *p < 0.05 vs Allo-MLR, Allo-MLR + freezed-thawed conditioned medium, Allo-MLR + <100 kDa fraction of conditioned medium).
proliferation was assessed with conditioned medium before and after size exclusion filtering. As expected, conditioned medium inhibited T cell proliferation and the activity was lost after freezing and thawing (Fig. 2D).

To rule out the possibility of dnnIKK2-DC-derived EV potentially contaminating dnnIKK2-Treg-EV, we prepared EV from dnnIKK2-Treg obtained at the end of allogeneic MLR with LN cells from DA rats. Through this approach we were able to obtain EV from sorted RT1A<sup>+</sup>CD4<sup>+</sup> DA dnnIKK2-Treg, without any contaminating BN dnnIKK2-DCs. Results showing that DA dnnIKK2-Treg-EV suppressed T cell proliferation like LW dnnIKK2-Treg-EV did, allowed us to exclude the possibility that the suppressive capacity of dnnIKK2-Treg-EV was due to contaminating EV of dnnIKK2-DC origin (Fig. 2E).

DnnIKK2-Treg-EV did not show alloantigen-specificity, indeed they suppressed T cell proliferation even toward third party allogeneic WF DCs (Fig. 2F, left panel). In addition EV from DA dnnIKK2-Treg suppressed proliferation of non autologous LW T cells toward BN DCs (Fig. 2F, right panel).

Suppression of T cell alloreactivity induced by dnnIKK2-Treg-EV has latency period. A time course of T cell alloreactivity with dnnIKK2-Treg-EV in allo-MLR is shown in Fig. 3. At day 3, dnnIKK2-Treg-EV inhibited T cell proliferation compared to naïve MLR, while Tact or Trest-EV did not affect T cell proliferation. At day4, dnnIKK2-Treg-EV completely suppressed T cell proliferation, which on the other hand further increased in all the control MLRs (Fig. 3A).

In line with the results of T cell proliferation and according to results obtained with EV from CD4<sup>+</sup>CD25<sup>+</sup>Foxp3<sup>+</sup>‘Treg’<sup>11</sup>, the evaluation of IFN-γ<sup>+</sup> clone generation showed that at day 3 dnnIKK2-Treg-EV inhibited the formation of clones of IFN-γ<sup>+</sup> producing cells. At day 4, IFN-γ<sup>+</sup> clones were almost undetectable when T cells were stimulated by allogeneic DCs in the presence of dnnIKK2-Treg-EV, whereas they further rose in all the control MLRs (Fig. 3B). Evidence that IFN-γ<sup>+</sup> producing cells were CD4<sup>+</sup>Th1/CD8<sup>+</sup> T<sub>Tc1</sub> cells emerged from experiments showing that the addition of a neutralizing anti-IL-12 antibody, the master cytokine for Th1/Tc1 clone formation, completely blocked T cell proliferation (Fig. 3C) and erased the number of IFN-γ<sup>+</sup> cell clones (Fig. 3D), both in MLR added with dnnIKK2-Treg-EV and in allo-MLR.

A higher amount of IL-10 was found in the supernatant of MLR performed with dnnIKK2-Treg-EV compared to all the control MLR conditions (Fig. 3E). However, the addition of an anti-IL-10 antibody did not restore T cell proliferation (Fig. 3F), indicating that the anti-proliferative effect of dnnIKK2-Treg-EV was not mediated by IL-10.

dnnIKK2-Treg-EV prevent cell cycle progression of quiescent T cells and induce apoptosis. Next we tested whether dnnIKK2-Treg-EV blocked the cell cycle progression of T cells in MLR. T cells in the G0/G1 cell cycle phase were stimulated by allogeneic DC in the presence of dnnIKK2-Treg-EV. After 4 days of MLR, T cells did not progress toward the S and G2 phases (Fig. 4A,B) but most of them (55 ± 8%) underwent apoptosis (subG1). In contrast, T cells stimulated by allogeneic DC in the presence of Tact-EV were in S (19 ± 8%) ± 5%) phases (p < 0.05 vs dnnIKK2-Treg-EV-exposed T cells), and the percentage of cells in subG1 was significantly lower (p < 0.05) than that of T cells exposed to dnnIKK2-Treg-EV (Fig. 4A,B). Consistently, the percentage of apoptotic T cells, as measured using TUNEL (Fig. 4C,D) or AnnexinV/7AAD staining (Supplementary Fig. 3), was higher after 4 days of MLR with dnnIKK2-Treg-EV compared to allo-MLR + Tact-EV. Western blot results showing a lack of FasL, granzyme B, perforin or galectin 9 in protein extracts from dnnIKK2-Treg-EV suggested that apoptosis was not dependent on these pro-apoptotic molecules (Supplementary Fig. 4). Cell cycle progression of T cells in allo-MLR was not influenced by Tact-EV, as shown by comparable cell cycle distribution at day 4 of MLR with or without Tact-EV (Supplementary Fig. 5).

The evaluation of cell division numbers revealed that the majority of T cells stimulated by allogeneic DC in the presence of dnnIKK2-Treg-EV did not undergo cell division (Fig. 4E). Only 10% of dnnIKK2-Treg-EV exposed T cells completed 7 rounds of division in contrast with 35% of T cells exposed to Tact-EV. Suppressive activity by dnnIKK2-Treg-EV was exerted when they were added within 6 hours of T cell stimulation, while it was lost when the addition occurred after 24 h (Fig. 4F), indicating that dnnIKK2-Treg-EV cannot exert suppressive activity on already proliferating/activated T cells. Similar results were obtained when target T cells were stimulated by ConA (Fig. 4F).

dnnIKK2-Treg-EV convert naïve T cells into Treg. Naïve T cells, exposed to dnnIKK2-Treg-EV during MLR, not only underwent a forced block in cell cycle progression but also a functional change. Indeed, T cells recovered from MLR with dnnIKK2-Treg-EV and co-cultured onto an allo-MLR (co-culture MLR), inhibited T cell proliferation compared to naïve MLR, while Tact or Trest-EV did not affect T cell proliferation (Fig. 4G). T cells exposed to dnnIKK2-Treg-EV did not express CD25 and FoxP3 (1.7 ± 0.7% of CD25<sup>+</sup>FoxP3<sup>+</sup> on CD3<sup>+</sup>CD4<sup>+</sup> dnnIKK2-Treg-EV-exposed T cells vs 5.7 ± 1.0% of CD25<sup>+</sup>FoxP3<sup>+</sup> on CD3<sup>+</sup>CD4<sup>+</sup> naïve T cells, n = 3, by FACS analysis, p = NS, Supplementary Fig. 6A) and did not need cell-to-cell contact with target T cells to exert regulatory activity that was fully mirrored by their conditioned medium (Fig. 4H). A greater amount of IL-10 was released from T cells exposed to dnnIKK2-Treg-EV as cpm. Results are mean ± SE. *p < 0.05 vs all groups (n = 3). (F) A 4-day Allo-MLR (1 × 10<sup>6</sup> LW lymph node cells + 10,000 WF mature DC, left panel, or + 10,000 BN mature DC, right panel) was performed +/- LW (left panel) or DA (right panel) dnnIKK2-Treg-EV. Proliferation was measured by incorporation of <sup>3</sup>H-Thymidine at day4 and expressed as cpm. Results are mean ± SE. *p < 0.05 vs all groups (n = 3).
Figure 3. Suppressive effect of dnIKK2-Treg-EV on T cell proliferation and activation has a latency period. (A,B). A 4-day allogeneic MLR (Allo-MLR, 1 × 10^6 LW lymph node cells plus 10,000 BN mature DC) was performed in the presence or absence of EV from 20,000 dnIKK2-Treg (dnIKK2-Treg-EV), or 20,000 activated T cells (Tact-EV) or 20,000 resting T cells (Trest-EV). At day 1, 3 and 4 of MLR, proliferation was measured by incorporation of ^3^H-Thymidine and expressed as cpm (A); frequency of IFN-γ-producing T cells was assessed by ELISPOT assay (B). Results are mean ± SE of 5 independent experiments. *p < 0.05 vs all groups at the same time point. °p < 0.05 vs naïve MLR + dnIKK2-Treg-EV at day 1. (C,D). A 4-day Allo-MLR was performed in the presence or absence of EV from 20,000 dnIKK2-Treg (dnIKK2-Treg-EV) +/- anti-IL-12 antibody. At day 1, 3 and 4 of MLR, proliferation was measured by incorporation of ^3^H-Thymidine and expressed as cpm (C); frequency of IFN-γ-producing T cells was assessed by ELISPOT assay (D). Results are mean ± SE of 3 independent experiments. *p < 0.05 vs all groups at the same time point. °p < 0.05 vs naïve MLR + dnIKK2-Treg-EV at day 1. #p < 0.05 vs without anti-IL-12. (E,F) A 4-day Allo-MLR was performed in the presence or absence of EV from 20,000 dnIKK2-Treg (dnIKK2-Treg-EV), or 20,000 activated T cells (Tact-EV) or 20,000 resting T cells (Trest-EV). IL-10 release was measured in the MLR supernatant at day1, 3 and 4 by ELISA assay. Results are expressed as mean ± SE of 5 independent experiments. *p < 0.05 vs all groups at the same time point. (F) A 4-day Allo-MLR was performed in the presence or absence of EV from 20,000 dnIKK2-Treg (dnIKK2-Treg-EV) +/- anti-IL-10 antibody. Proliferation was measured by incorporation of ^3^H-Thymidine at day1, 3 and 4 of MLR and expressed as cpm. Results are mean of 2 independent experiments.
Figure 4. Effect of dnIKK2-Treg-EV on cell cycle progression and apoptosis. (A,B) Cell cycle distribution in dnIKK2-Treg-EV-exposed Tcells. A 4-day Allo-MLR (1 \times 10^6 LW lymph-node cells + 10,000 BN mature DC) was performed with dnIKK2-Treg-EV or Tact-EV. (A): percentages of T cells in sub-G0/G1, G0/G1, S and G2/M phases. Mean ± SD (n = 4 independent experiments). *p < 0.05 vs all groups in the same cell cycle phase. (B): Representative FACS histograms of PI staining and gates at day 0 (upper histogram) or 4 of MLR (+dnIKK2-Treg-EV: central histogram; +Tact-EV: lower histogram). (C–D) Apoptosis in dnIKK2-Treg-EV-exposed Tcells. (C): Percentages of TUNEL+ cells (by FACS). Mean ± SD (n = 3 independent experiments). *p < 0.05 vs day4 Allo-MLR+Tact-EV. (D): Representative FACS histograms. (E) Numbers of cell divisions in dnIKK2-Treg-EV-exposed Tcells. A 4-day Allo-MLR was performed with dnIKK2-Treg-EV or Tact-EV. Cell division number was evaluated by FlowJo software after FACS-analysis of CFSE-labeling on 7-AAD− cells. Mean ± SD (n = 4 independent experiments). *p < 0.05 vs corresponding Allo-MLR+Tact-EV. (F) dnIKK2-Treg-EV suppress cell proliferation only when given early during T cell stimulation. T cells were stimulated with allogeneic DC (Allo-MLR, upper
DNIIK2-Treg-EV contain a subset of specific miRNA. EV can act as an intercellular shuttle of RNA and miRNAs. To assess whether DNIIK2-Treg-EV exert their suppressive function through miRNAs, their profile was assessed in DNIIK2-Treg-EV, Tact-EV and Trest-EV. A total of 87 miRNAs was detected, of which 56 were exclusively expressed in DNIIK2-Treg-EV (Supplementary Tables 1 and 2). Of the latter, 9 were highly expressed with threshold cycle (Ct) values below 30. RT-PCR validation of these 9 miRNAs confirmed the high expression of 7 miRNAs, of which 3 (miR-503, miR-330 and miR-293) were exclusively expressed in DNIIK2-Treg-EV, while the remaining 4 miRNAs (miR-297c, miR-207, miR-9, miR-484) were faintly expressed in Tact-EV and Trest-EV too (Fig. 5A).

Target predictions and pathway analysis for the 7 miRNAs were performed with miRPath software based on gene-miRNA interactions validated in humans. This analysis highlighted 3 miRNAs (miR-503, miR-330 and miR-9) potentially affecting 16 pathways (Supplementary Table 3) among which cell cycle was the most closely related to anti-proliferative effects of DNIIK2-Treg-EV. Target prediction of cell cycle genes targeted by miR-503, miR-330 and miR-9 included CCNE1, CCNE2, CCND1, CDC14A, E2F1-3, CDKN1A, CDC25A, CHEK1, WEE1 and EP300 (Supplementary Fig. 8). Notably, the expression of Cyclin E and Cyclin D1, two predicted targets crucial for G1 phase execution and G1/S progression, was lower in T cells exposed to DNIIK2-Treg-EV during MLR compared to T cells activated in the absence of DNIIK2-Treg-EV (Fig. 5B,C). Tact-EV did not influence expression of Cyclin E and Cyclin D1 in T cells stimulated by allogeneic DC in MLR (Supplementary Fig. 9).

To investigate the role of the miRNAs in the suppressive activity of DNIIK2-Treg-EV, EV of DNIIK2-Treg were obtained in the presence of poly-L-lysine (PLL) and trypallavine (TPF), small molecules affecting miRNA generation and stability. DNIIK2-Treg-EV inhibition of T cell proliferation, evaluated at day 4 of MLR, was not completely restored by PLL/TPF (Fig. 5D). Specificity of miRNA inhibition by PLL/TPF treatment was documented by results of RT-PCR showing that miR503 was undetectable (Ct values > 40) in EV released from PLL/TPF-treated DNIIK2-Treg, at variance with EV from untreated DNIIK2-Treg (Ct values < 35).

DNIIK2-Treg-EV contain iNOS mRNA and protein. Since miRNA cargo did not fully account for the anti-proliferative effect of DNIIK2-Treg-EV and on the basis of our previously reported data on iNOS mRNA and protein expression in DNIIK2-Treg-EV, we further assessed whether iNOS was shuttled in DNIIK2-Treg-EV. Real-time PCR showed that iNOS mRNA was present within DNIIK2-Treg-EV at a significantly higher level than that found in control Trest-EV (Fig. 6A). Consistently, Western blot analysis revealed a strong specific signal for iNOS in protein extracts from DNIIK2-Treg-EV, which was higher than that of DNIIK2-Treg (Fig. 6B), suggesting selective transfer of iNOS protein in EV. In addition, Western blot analysis revealed that cells exposed to DNIIK2-Treg-EV during MLR displayed a 4-fold higher iNOS expression than that recorded in allo-MLR (Fig. 6C,D), indicating that iNOS mRNA and protein were transferred from DNIIK2-Treg-EV to T cells. Tact-EV did not influence expression of iNOS in T cells stimulated by allogeneic DC in MLR (Supplementary Fig. 9).

To investigate the involvement of iNOS in the suppressive effect of DNIIK2-Treg-EV, MLR experiments were repeated in the presence of the NOS inhibitor N-ω-nitro-L-arginine. T cell proliferation and IFNγ+ T cell clone formation partially but significantly recovered in the presence of N-ω-nitro-L-arginine (Fig. 6E). T cell proliferation in allo-MLR, as well as in MLR with Tact-EV or Trest-EV, was not affected by N-ω-nitro-L-arginine (Fig. 6E).
The addition of the membrane-impermeable NO-scavenger carboxy-PTIO did not affect the anti-proliferative activity of dnIKK2-Treg-EV, indicating that the suppressive effect was due to iNOS enzyme within dnIKK2-Treg-EV (Fig. 6F).

The whole molecular cargo of dnIKK2-Treg-EV is essential for their anti-proliferative effect. To assess whether the whole molecular cargo of dnIKK2-Treg-EV, miRNAs and iNOS, was required for them in order to exert their anti-proliferative effect, MLR experiments were repeated with both EV of dnIKK2-Treg obtained in the presence of PLL/TPF (PLL/TPF-dnIKK2-Treg-EV) and N-ω-nitro-L-arginine. EV of Trest obtained in the presence of PLL/TPF (PLL/TPF-Trest-EV) were used as controls. As shown in Fig. 7A, the combined inhibition of miRNA and iNOS did not affect T cell proliferation in the presence of control Trest-EV while it completely abolished the anti-proliferative effect induced by dnIKK2-Treg-EV. According to the results of T cell proliferation, the inhibition of both miRNA and iNOS restored the expression of CyclinE and CyclinD1 in T cells exposed to dnIKK2-Treg-EV during MLR, as shown by results of comparable expression levels of Cyclin E and Cyclin D1 in protein extracts of T cells from MLR with PLL/TPF-dnIKK2-Treg-EV and N-ω-nitro-L-arginine and T cells from control MLR (Fig. 7B,C).

Furthermore, the combined inhibition of miRNA and iNOS abolished the pro-apoptotic effect of dnIKK2-Treg-EV. In fact, at the end of MLR performed in the presence of PLL/TPF-dnIKK2-Treg-EV and N-ω-nitro-L-arginine, the percentage of apoptotic T cells was similar to that observed at the end of control
MLR and significantly \( p < 0.05 \) lower than that observed at the end of MLR performed in the presence of dnIKK2-Treg-EV (Fig. 7D).

**DnIKK2-Treg-EV prolong kidney allograft survival.** Finally, we verified whether dnIKK2-Treg-EV had immunoregulatory function *in-vivo* in the MHC-mismatched BN (RT1\(^n\)) to LW (RT1\(^l\)) rat model of kidney allotransplantation\(^29\). The intravenous injection of dnIKK2-Treg-EV in LW recipient animals induced a modest,
and not significant, prolongation of allograft survival (15 ± 6 vs 8 ± 2 days in vehicle-treated rats, mean ± SD, Fig. 8A). Death was preceded by a sudden rise of serum creatinine of 2 to 5 mg/dL in both groups (Fig. 8B) indicating that animals died of acute graft rejection.

Since splenic T cells are mainly responsible for early acute allograft rejection 30, 31, we administered dnIKK2-Treg-EV via intrasplenic inoculation to recipient rats. No significant allograft survival prolongation was observed when recipient rats received dnIKK2-Treg-EV in the spleen (12 ± 2 days post-transplant, n = 3, mean ± SD, Fig. 8A).

Figure 7. Suppressive effect of dnIKK2-Treg-EV depends on their whole molecular cargo. (A) Effect of PLL/TPF-dnIKK2-Treg-EV in combination with NOS inhibition on T cell proliferation. An allogeneic MLR (Allo-MLR, 1 × 10^6 LW lymph node cells plus 10,000 BN mature DC) was performed in the presence of EV from 20,000 dnIKK2-Treg treated with poly-L-lysine (PLL) and trypaflavine (TPF) (PLL/TPF-dnIKK2-Treg-EV), or 20,000 dnIKK2-Treg (dnIKK2-Treg-EV), or 20,000 dnIKK2-Treg treated with PLL/TPF (PLL/TPF-dnIKK2-Treg-EV) + / − N-ω-nitro-L-arginine (NitroArg). Proliferation was measured by incorporation of ^3^H-Thymidine at day 4 of MLR and expressed as cpm. Results are expressed as mean ± SE of 3 independent experiments. \(^*p < 0.05\) vs all groups. (B,C) Expression and quantification of Cyclin E and Cyclin D1 in cells from allogeneic MLR performed in the presence of PLL/TPF-dnIKK2-Treg-EV + NOS inhibition. (B) Western blot analysis of Cyclin E, Cyclin D1 and β-actin in protein extracts of cells from day 3 MLR with (central lane) or without (left lane) dnIKK2-Treg-EV, or day 3 MLR with PLL/TPF-dnIKK2-Treg-EV in combination with N-ω-nitro-L-arginine (NitroArg) (right lane). 20 μg of total proteins were loaded for each lane. Blots were cropped. Molecular weights are given on the left. One representative experiment of 3 is shown. (C) results of densitometric analysis are given, after normalization with β-actin, as % of relative expression, considering Allo-MLR as 100%. Mean ± SD of 3 independent experiments. \(^*p < 0.05\) vs all corresponding groups. (D) Evaluation of apoptotic cells. FACS analysis of apoptotic cells (by TUNEL assay) at day 0 or day 4 of MLR with or without dnIKK2-Treg-EV, or day 4 of MLR with PLL/TPF-dnIKK2-Treg-EV in combination with N-ω-nitro-L-arginine (NitroArg). The numbers in the histograms give the percentage of apoptotic cells (TUNEL positive cells). One representative experiment of 3 is shown.
Figure 8. Effect of dnIKK2-Treg-EV on kidney allograft survival. (A) Kaplan-Meier analysis of survival. LW recipient rats were treated with EV released by either $100 \times 10^6$ (for the intravenous administration route, i.v.) or $25 \times 10^6$ (for the intrasplenic administration route, i.s.) dnIKK2-Treg (dnIKK2-Treg-EV). Control groups were i.v. or i.s. treated with vehicle (PBS). The day after i.v. or the day of i.s. dnIKK2-Treg-EV administration, recipient rats were subjected to BN kidney transplantation. Three groups did not receive immunosuppression ($n=3/4$ each group), whereas three groups were CsA treated for 4 days after transplantation ($n=3/4$ each group). DnIKK2-Treg-EV, administered either i.v. or i.s. and given together with 4-day CsA treatment, significantly prolonged kidney allograft survival (Log-rank test, $p<0.01$ vs all the other groups). (B) Graft function in kidney allotransplanted rats. Serum creatinine levels in LW rats receiving a BN kidney allograft at 7–90 days post-transplant. Results are mean ± SD. *$p<0.05$ vs corresponding group receiving CsA alone. (C) Ex-vivo studies. Left panel: a 4-day allogeneic MLR was performed with $1 \times 10^6$ irradiated BN splenocytes and $1 \times 10^6$ lymph node cells from naïve LW rats ($n=3$) or rats treated with 4 day CsA + dnIKK2-Treg-EV, receiving a BN kidney transplant and long-term surviving (>60 days post-transplant, $n=3$). Results are mean ± SD.
To delay acute graft rejection, giving enough time to dnIKK2-Treg-EV to exert their anti-proliferative effect, dnIKK2-Treg-EV were administered together with a four-day Cyclosporine (CsA) treatment. CsA-treated animals showed allograft rejection within 19 days post-transplant (16 ± 3 days post-transplant, n = 3, mean ± SD, Fig. 8A,B). In contrast, when recipient rats were CsA-treated and received dnIKK2-Treg-EV i.v., allograft survival was further prolonged (38 ± 16 days post-transplant, mean ± SD, n = 3, p < 0.01 vs all groups). More importantly, intrasplenic administration of dnIKK2-Treg-EV, together with the short course of CsA, prevented acute rejection and prolonged allograft survival compared with animals that received dnIKK2-Treg-EV injections i.v. (73 ± 34 days post-transplant, mean ± SD, n = 4, p < 0.01 vs all groups, Fig. 8A), with 75% of recipient rats achieving long-term allograft survival (>60 days post-transplant) and displaying stable renal function (Fig. 8B).

As compared to naïve T cells, T cells obtained from lymph nodes of long-term surviving rats were hyporesponsive vs donor alloantigens (Fig. 8C, left panel). Co-culture experiments documented that T cells from long-term surviving rats suppressed naïve T cell proliferation toward BN alloantigens (Fig. 8C, right panel). Suppressive effect was fully reverted by addition of N-ω-nitro-L-arginine to co-culture MLR, suggesting that iNOS activity might play a crucial role in such regulatory function (Fig. 8C, right panel). By FACS analysis, the percentage of CD25+FoxP3+ T cells was not different between long-term surviving (6.4 ± 1.9% CD25+FoxP3+ on CD3+CD4+ T cells, n = 3) and naïve rats (5.7 ± 1.0% CD25+FoxP3+ on CD3+CD4+ T cells, n = 3, Supplementary Fig. 10), confirming in-vivo that Treg formed by dnIKK2-Treg-EV were not CD25+FoxP3+.

Discussion
In this report we document that dnIKK2-Treg release EV riched in exosomes which potently suppress T cell proliferation, fully mirroring the cell-contact independent immunosuppressive activity of their parent cells.

EV, once they reach the target cells, can be internalized21, thereby releasing their content into the cytosol21, and modifying or reprogramming the recipient cells21, 34. Our finding here that dnIKK2-Treg-EV are taken up by target T cells and that their T cell suppressive activity depends on EV integrity, indicates that the anti-proliferative effect of dnIKK2-Treg-EV relies on the delivery of their cargo into naïve T cells.

In search of mediators of the T cell anti-proliferative effect of dnIKK2-Treg-EV, we focused on microRNAs (miRNAs), based on data that cell-derived EV and exosomes can contain miRNAs which are delivered to another cell, where they can be functional10, 31, 36, 37. The analysis of miRNA levels showed that the miRNA cargo of dnIKK2-Treg-EV makes them unique and different from Tact-EV or Trest-EV.

Okoye et al. have recently documented that murine CD4+CD25+FoxP3+Treg release miRNA-containing exosomes, that transfer Let-7b, Let-7d and miR-155 into Th1 cells, contributing to suppressing Th1 activation and inflammation in murine colitis32. The mechanism seems to involve decreased IFN-γ secretion in Th1 cells following a possible Let-7d-induced Cox-2 inhibition. DnIKK2-Treg-EV, described here, also reduced the formation of IFN-γ+ T cell clones, but differed from the Treg-derived-exosomes described by Okoye et al. Firstly, the dnIKK2-Treg-EV inhibited T cell activation as effectively as dnIKK2-Treg, consistent with our previous finding that cell-to-cell contact was not essential for their parent cells in order to be suppressive. Second, we did not detect Let-7d in dnIKK2-Treg-EV, but other specific miRNAs. Namely, miR-503, miR-330 and miR-9, which affect the transcription of genes encoding proteins crucial to the regulation of cell cycle progression, were exclusively present or were up-regulated in dnIKK2-Treg-EV compared to Tact-EV or Trest-EV. There is evidence that the over-expression of miR-503 induces a G1 cell cycle arrest in several cell lines by down-regulating genes such as CCNE1 (Cyclin E1), CCND1 (Cyclin D1), CDKN1A (Cip1, p21), CDC25A (Cdc25A phosphatase), CHEK1 (Chk1 kinase) and WEE1 (Wee1 kinase) both at mRNA and at the protein level38, 40. Our findings – that Cyclin E and Cyclin D1 proteins are down-regulated in T cells exposed to dnIKK2-Treg-EV, together with the arrest of T cell cycle progression – confirm that miR-503 has a role in cell cycle regulation in this setting. However, miRNA delivery did not account for 100% of the anti-proliferative effect of dnIKK2-Treg-EV, suggesting the presence of additional anti-proliferative molecules.

In search of additional mediators, we focused on iNOS, which we previously demonstrated was expressed in dnIKK2-Treg. Here we show that the iNOS mRNA and protein were present in dnIKK2-Treg-EV, with the protein appearing more concentrated in the EV compared to the parent Treg. To the best of our knowledge, this is the first report showing the iNOS enzyme within extracellular vesicles. In 1995, a report described a membrane-associated iNOS isoform within 50–80 nm intracellular vesicles, not corresponding to lysosomes or peroxisomes41. It is tempting to speculate that the previously documented iNOS-containing intracellular vesicles41 and those shown here are the same vesicles, the latter being the extracellular counterparts of the former.

The results of higher iNOS expression in T cells exposed to dnIKK2-Treg-EV, compared to unexposed T cells, would indicate that iNOS mRNA and protein were delivered by the EV into target cells, with intracellular NO-mediated anti-proliferative, cytotoxic and apoptotic effects42, 43. In this regard, the over-expression of NOS in human aortic vascular smooth muscle cells was accompanied by lack of cell proliferation and apoptosis44. Similarly, in human breast cancer cells exposure to a NO donor caused the arrest of cell cycle progression. This effect was due to a decrease in cyclin D1 synthesis45, which was in line with our present data that iNOS-containing EV induced the down-regulation of the cyclin D1 protein and cell cycle arrest in T cells.
However, dnIKK2-Treg-EV induced anti-proliferative activity was not entirely due to iNOS, even though it was delivered in an enzymatically active state, as indicated by results showing that N-ω-nitro-L-arginine, but not carboxy-PTIO, a cell-impermeable NO-scavenger, partially recovered the proliferative capacity of dnIKK2-Treg-EV-exposed T cells.

Notably, we found that neither miRNAs nor iNOS accounted by themselves for the anti-proliferative and pro-apoptotic effects of dnIKK2-Treg-EV. Only the combined inhibition of miRNAs and iNOS completely restored proliferation and prevented apoptosis in dnIKK2-Treg-EV-exposed T cells, indicating that the whole molecular cargo inhibited T cell alloreactivity. Our data implicate that miRNA and iNOS delivery into T cells by EV blocked cell cycle progression and increased intracellular NO production leading to apoptosis (summarized in Fig. 8D).

DnIKK2-Treg-EV not only inhibited T cell proliferation but also induced target T cells to acquire a regulatory function that is FoxP3 independent. Finding that T cells exposed to dnIKK2-Treg-EV released high amount of IL-10 and suppressed without needing cell-to-cell contact, would suggest that they possess a Tr1-like phenotype rather than a CD25+FoxP3+ T-like phenotype. However, results showing that, at variance with Tr1 cells, T cells exposed to dnIKK2-Treg-EV did not co-express CD49b and LAG3, rule out such possibility. As compared to naïve and activated T cells, the large majority of T cells exposed to dnIKK2-Treg-EV during MLR expressed Tim3, an inhibitory receptor expressed by a unique CD4+- Treg population recently described. The exact phenotype of the unconventional induced Treg here reported remains unclear and it is worth of further investigations. However, conversion into Treg exerted by EV derived by dnIKK2-Treg could be reminiscent of the model of infectious tolerance described by Waldmann who first proposed that tolerance can be passed on from one population of lymphocytes to another.

Formation of dnIKK2-Treg-EV-converted Treg could be explained by the link coupling cell cycle regulation and Treg differentiation provided by data that human CD4+CD25− T cells treated with anti-CD3/anti-CD28 together with the vasoactive intestinal peptide underwent cell cycle arrest and acquired T cell suppressive activities. Moreover, the down-regulation of cell cycle and Foxo family genes resulted in reprogramming and the conversion of diabetogenic autoreactive T cells to Treg that did not need cell-to-cell contact with target cells, similarly to dnIKK2-Treg-EV-converted Treg here described. Furthermore, modulating cell cycle in T cells plays a role in acquired peripheral tolerance to alloantigens, as Treg from cdk-2 deficient mice display enhanced immunosuppressive function and cdk-2 deficient mice failed to reject a cardiac allograft due to the presence of fewer Th1 and more Foxp3+ Treg in tolerated grafts compared to rejected grafts from wild type recipients.

Consistent with in-vitro data, here we found that treatment with dnIKK2-Treg-EV significantly prolonged kidney allograft survival. Graft survival was more prolonged when dnIKK2-Treg-EV were administered into the recipient spleen, rather than through i.v. injection, according to data documenting that splenic T cells are the main initiators of acute rejection in vascularized transplant models. Notably, prolonging allograft survival required that dnIKK2-Treg-EV be given together with a 4-day CsA treatment, which per se did not prevent acute rejection. We hypothesized that the 4-day CsA treatment controlled T cell response until dnIKK2-Treg-EV were fully effective, in line with in-vitro results showing that the anti-proliferative effect of dnIKK2-Treg-EV was fully achieved after 4 days of MLR. Finding that T cells harvested from long-term surviving transplanted rats treated with dnIKK2-Treg-EV were hyporesponsive and exerted regulatory function by a mechanism that was dependent on NOS activity, would suggest that dnIKK2-Treg-EV regulated T cell proliferation through similar mechanisms, both in-vivo and in-vitro. Despite the powerful regulatory function, we recognize that dnIKK2-Treg-EV are deprived of antigen specific effect in-vitro. However, it could be tempting to speculate that in-vivo, in the context of alloantigen specific T cell stimulation as it occurs in allograft rejection, the suppressive effect of dnIKK2-Treg-EV could result in an antigen specific suppression, as we previously documented in transplanted animals treated with the parent cells dnIKK2-Treg.

Altogether our results show that EV released from dnIKK2-Treg possess a unique molecular cargo, composed by specific miRNAs and iNOS which, once delivered into T cells, inhibited T cell alloreactivity in-vitro and in-vivo by perturbing cell cycle progression, inducing apoptosis, and converting target T cells into Treg. The use of EV, as compared to their parent cells as therapy to induce immune tolerance in transplantation, could offer some advantages due to the fully cell-free approach, the stable nature of EV after in-vivo infusion as well as the easy storage. DnIKK2-Treg-derived EV could be a tool for manipulating the immune system in recipients of solid organ transplants and can open an unanticipated possibility to discover novel potential immunosuppressive molecules to be exploited in the context of allograft transplantation.

**Materials and Methods**

**Animals and ethics statement.** Male inbred Brown Norway (RT1<sup>a</sup>, BN, Charles River, Calco, Italy), DA (RT1<sup>b</sup>, DA, Charles River), Lewis (RT1<sup>c</sup>, LW, Charles River) and Wistar Furth (RT1<sup>s</sup>, WF, Charles River) rats weighing 210 to 250 g (3 months old) were used. These animals differ for class I, class II and non-MHC genes. Procedures involving animals and their care were conducted in conformity with the following laws, regulations and policies governing the care and use of laboratory animals: Italian Governing Law (D.lgs 26/2014; Authorization n.19/2008) issued March 6, 2008 by Ministry of Health); the NIH Guide for the Care and Use of Laboratory Animals (2011 edition) and EU directives and guidelines (EEC Council Directive 2010/63/UE).

Animal experimental protocols have been approved by our Institutional Committee (IACUC, IRFMN Animal Care and Use Committee) at “IRCCS-Istituto di Ricerche Farmacologiche Mario Negri”, which includes members “ad hoc” for ethical issues. Animals were housed in the Institute’s Animal Care facilities which meet international standards. They were regularly checked by a certified veterinarian who is responsible for health monitoring, animal welfare supervision, experimental protocols and procedures revision.
Generation of CD4\(^+\) dnlKK2-regulatory T cells, CD4\(^+\) activated T cells and CD4\(^+\) resting T cells.

Brown–Norway bone marrow–derived immature or mature DC were obtained as previously described\(^6,7\). Briefly, DC were made immature by transfection with adenovirus-encoding dnlKK2 (dnlKK2-DC), whereas DC transfected with empty adenovirus (AdV0-DC) were considered control mature DCs. dnlKK2-DC or AdV0-DC were used as stimulators in a 4-day allogeneic primary mixed leukocyte reaction (MLR) with Lewis (LW) lymph node cells (LN) as responders (1:100 DC/responder ratio). In selected experiments DA lymph node cells were used as responders. At the end of MLR, cells were stained with APC-conjugated anti-rat CD4 (OX35 clone, eBioscience) and CD4\(^+\) T cells were sorted by FACS (FACSortia, BD, purity: 90–95% on average) to obtain CD4\(^+\) regulatory T cells (here called dnlIKK2-Treg) or CD4\(^+\)-activated T cells (named Tact), respectively, as previously described\(^6,7\). Sorted CD4\(^+\) dnlIKK2-Treg or Tact were then stained by FITC-conjugated anti-CD11c antibody and FACS-analyzed. CD4\(^+\) sorted cells did not express CD11c marker. Despite this result, suggesting the absence of DC in dnlIKK2-Treg preparation, additional experiments were performed to completely rule out the presence of dnlKK2-DC within dnlIKK2-Treg. In detail, LN cells from DA rats were stimulated by BN dnlKK2-DC in a 4-day MLR. At the end of the MLR cells were stained with a mouse anti-rat RT1A\(^+\) antibody (anti-DA MHC class I, clone MN4-91-6, AbDSerotec), followed by FITC-conjugated anti mouse secondary antibody (Invitrogen), and APC-conjugated anti-CD4 antibody. Sorted DA RT1A\(^+\) CD4\(^+\) dnlIKK2-Treg were 100% negative for CD11c expression. APC and FITC-conjugated control isotype antibodies were used as negative controls. LN cells were cultured alone for 4 days and then FACS-sorted to obtain resting CD4\(^+\) T cells (here called Trest).

In order to obtain either dnlIKK2-Treg or Trest incapable of generating miRNAs, LN cells were cultured for 4 days, with or without dnlKK2-DC respectively, in the presence of poly-L-lysine (5 \(\mu\)M, poly-L-lysine hydrobromide, MW 4,000–15,000, Sigma Aldrich) and trypallavine (8\(\mu\)M, 3,6-diamino-10-methylacridinium chloride, Sigma Aldrich), two non-cytotoxic small molecules affecting miRNA generation and stability\(^6,7\).

DnlIKK2-Treg (both from DA and LW rat), or Tact, or Trest were incubated alone (2 \(\times\) 10\(^6\)/ml) for 18 h in medium supplemented with exosome-free fetal bovine serum (FBS, overnight centrifugation, 100,000 g) to obtain conditioned medium. In selected experiments dnlIKK2-Treg were stained with 0.5 \(\mu\)M carboxyfluorescein-succinimidyl ester (CFSE) before the 18 h incubation. In additional experiments, conditioned medium from dnlKK2-Treg was subjected to size exclusion filtering (100kDa, Merck Millipore) or freeze and thaw cycles.

Preparation of EV from conditioned medium. Extracellular vesicles (EV) were purified from conditioned medium of dnlKK2-Treg or Tact or Trest, as previously reported\(^6,8\) and as also suggested by the position paper from the International Society for Extracellular Vesicles\(^22,23\). Conditioned medium was centrifuged at 300 g (10 min), 1,200 g (20 min), 10,000 g (30 min), filtered (0.22 \(\mu\)m) and then ultracentrifuged (100,000 g, 1 h, 4°C, by swinging bucket rotor), washed in PBS and again ultracentrifuged. The pellet from ultracentrifugation of conditioned medium from about 20 \(\times\) 10\(^6\) dnlIKK2-Treg or Tact or Trest was resuspended in about 200 \(\mu\)l PBS (corresponding to a concentration of EV released from 100,000 cells/\(\mu\)l) and then used in vitro in MLR experiments. In selected experiments, before adding to MLR, EV were subjected to 4–5 cycles of freeze and thaw, or PKH26 stained, or were treated with 10 \(\mu\)g/mL of RNaseA (Ambion Inc.) for 1 h at 37°C, followed by 10 U/mL of RNase inhibitor, subjected to ultracentrifugation followed by protein content assessment to add a comparable amount of RNase-treated or untreated EV to MLR. As shown in supplementary Fig. 11, RNase-treated dnlIKK2-Treg-EV were still able to inhibit T cell proliferation toward allogeneic DCs, suggesting that biological function of EV was not associated with RNA being present on their exterior, as also shown by Valadi et al.\(^37\). Since ultracentrifugation could also pellet protein complexes present in the conditioned medium, to evaluate whether possible co-precipitated proteins contributed to the biological function of EV, we fractionated proteins of medium conditioned from dnlIKK2-Treg by HPLC and tested each protein fraction. Results that no protein fraction exerted the suppressive effect observed either with dnlIKK2-Treg conditioned medium (pre-HPLC) or with dnlIKK2-Treg-EV obtained by the same conditioned medium, would rule out the possibility that precipitated proteins might be responsible for the suppressive effect (Supplementary Fig. 12).

In additional experiments, EV from dnlKK2-Treg were fixed in 2% paraformaldehyde for electron microscopy analysis or conjugated to latex-beads for FACS-analysis of surface antigens. Selected EV preparations were used for protein or RNA extraction. In selected experiments PKH26-labeled EV from 200,000 dnlKK2-Treg were incubated with naive T cells (1 \(\times\) 10\(^6\)) and 24–48 h later T cells were FACS-analyzed for PKH26 expression.

FACS analysis. For FACS analysis EV were first PKH26-labeled using a commercially available kit (Sigma-Aldrich) according to the manufacturer’s instructions. The efficiency of labeling of the EV (determined by FACS) was on average 90–100%. PKH26-labeled EV were attached to 4 \(\mu\)m aldehyde/sulfate latex beads and FACS-analyzed. FITC or AF647-conjugated control isotype antibodies were used as negative controls.

Antibodies used for FACS analysis of FoxP3\(^+\) Treg were FITC-anti-rat CD3 (1F4, Biologend), APC-Cy7-anti-rat CD4 (W3/25, Biologend), PE-anti-rat CD25 (OX-39, Biologend) and AF647-anti-mouse/human/rat FoxP3 (150D, Biologend). Staining was performed on fixed and permeabilized cells from lymph nodes (Permeabilization/Fixation Kit, eBioscience). FACS analysis was performed on viable cells (ViaProbe Cell Viability Solution, BD) by FACS LSR FortessaX-20 (BD).
Antibodies used for FACS analysis of CD49b+ LAG3+ Treg were hamster anti rat CD49b (HA1/29, BD Pharmingen) followed by FITC-mouse-anti-Armenian and Syrian Hamster IgG cocktail (BD Pharmingen); rabbit anti-rat LAG3 (LifeSpan Biosciences) followed by PE-rat-anti-rabbit Ig (Southern Biotech); APC-anti-rat CD3 (1F4, BD Pharmingen) and APC-Cy7-anti-rat CD4 (W3/25, BioLegend). Antibodies used for FACS analysis of Tim3+ CD3+ cells were FITC-conjugated anti-rat Tim3 (Biorbyt) and APC-conjugated anti-rat CD3 (1F4, BD Pharmingen). FACS analysis was performed by FACS LS FortessaX-20 (BD).

Electron microscopy analysis. The EV sample was fixed in 2% paraformaldehyde, and then loaded to copper grids (100 mesh) coated with Formvar. After washing, the grids were contrasted in 2% uranyl acetate, dried, and then examined by transmission electron microscopy (Morgagni 268D; Philips). The identity of the vesicles as exosomes was confirmed by the presence of the tetraspan surface protein CD63 by immunogold labeling of the grids overnight at room temperature with primary antibody for CD63 (dilution 1:100, BD Pharmingen). The grids were then exposed for 1 h to species-specific anti-IgG antibody conjugated to 12 nm colloidal particles.

RNA isolation and Real-time PCR analysis. Total RNA was isolated using mirVana Isolation Kit (Ambion) according to the manufacturer’s protocol (for dnIKK2-Treg-EV and Trest-EV) or Trizol (for T cells). Contaminating genomic DNA was removed by RNase-free DNase (Promega) for 1 h at 37 °C. The purified RNA (150 ng for dnIKK2-Treg-EV and Trest-EV and 2.5 µg for T cells) was reverse transcribed using VILO SuperScript RT (Invitrogen). No enzyme was added for reverse transcriptase-negative controls.

To amplify cDNA we used SYBR Green PCR Master Mix (Applied Biosystems) according to the manufacturer’s instructions. Primers used to amplify inOS, Cld4, Tim3, PD1, Lag3, Itgaa2 (CD49b) and Gapdh, used as endogenous control, were described in supplementary Table 4. We used the ΔΔCt technique to calculate cDNA content in each sample using as calibrator the cDNA expression in dnIKK2-Treg-EV or in T cells from day0 Allo-MLR, as specified.

miRNA profiling. The amount of isolated RNA was analysed by NanoDrop ND-1000 (ThermoScientific). EV released from 10⁶ dnIKK2-Treg or Tact or Trest contained 20–30, 10–20, and 10–15 ng of total RNA respectively. The expression of microRNAs (miRNAs) in EV was profiled using stem-loop quantitative RT-PCR (qRT-PCR) miRNA assays on TaqMan low-density array cards (TLDA) (Rodent Array Card A v2.0, Applied Biosystems). The cards containing assays for 375 Rodent mature miRNAs present in the Sanger miRBase v13.0. qRT-PCRs were performed with Megaplex Primers Pool A according to the manufacturer’s instructions. Total RNA (3 µl per sample/card, ~350 ng total RNA) was reverse transcribed using TaqMan miRNA Reverse Transcription Kit (Applied Biosystems) with Megaplex Primers Pool A (Applied Biosystems). The complementary DNA (cDNA) was run on TLDA cards on ViiA7 Real Time PCR System (Applied Biosystems) using the manufacturer’s recommended cycling conditions (50°C for 2 min, 95°C for 10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min, with data collection at the end of each cycle). Threshold cycle (Ct) values > 35 were considered to be below the detection level of the assays, designated ‘undetected’ and excluded from data analysis. Data were analysed using the ΔΔCt method with dnIKK2-Treg-EV as the reference and small nuclear RNA (snRNA) U6 as endogenous control.

miRNA validation assays. Individual TaqMan miRNA assays (Applied Biosystems) were performed according to the manufacturer’s instructions. Total RNA (10 ng in 5 µl per sample) isolated from EV was converted to cDNA using the microRNA reverse transcriptase Kit (Applied Biosystems) with 3 µl of specific miRNA assay RT primer in a reaction volume of 15 µl. The cDNA was setup in triplicate qRT-PCRs containing 1 µl of specific TaqMan miRNA assay and run on ViiA7 Real Time PCR System (Applied Biosystems). Data were analysed using the ΔΔCt method with dnIKK2-Treg-EV as the reference and snRNA U6 as the endogenous control. Specific TaqMan miRNA assays used in this study were: U6 snRNA assay ID 001973, mmu-miR-293 ID 001794, hsa-miR-330-5p Assay ID 002456, hsa-miR-9 Assay ID 00058, hsa-miR-126-5p Assay ID 000451, rno-miR-207 Assay ID 001315, mmu-miR-297c Assay ID 002480, hsa-miR-484Assay ID 001821.

Western blot analysis. At the end of ultracentrifugation, EV were resuspended in 0.1 ml lysis buffer (50 mM–glycerolphosphate, 2 mM MgCl₂, 1 mM EGTA, 0.5% Triton X-100, 0.5% NP-40, 1 mM DTT, 1 mM pepstatin, 20 mM leupeptin, 1000 U/ml aprotinin, Sigma), and then subjected to 4–5 cycles of freeze and thaw. On average, EV released from 10⁶ dnIKK2-Treg contained 2–3 µg of proteins (quantified by the Bradford method, BioRad). Then, proteins were separated on denaturing sodium dodecyl sulfate polyacrylamide gel by electrophoresis, blotted to PVDF membrane, blocked with 5% milk and then incubated with primary antibody (polyclonal goat anti-CD63, T-14, sc25183, Santa Cruz, Santa Cruz, CA, USA; monoclonal mouse anti-tsg101, C-2, sc7964, Santa Cruz; polyclonal goat anti-calnexin, C-20, sc6465, Santa Cruz; polyclonal rabbit anti-inOS, BD Transduction Laboratories, or polyclonal rabbit anti-actin, aa20–33, Sigma-Aldrich, St Louis, MO, USA). Enhanced chemiluminescence (ECL) Advance (Amersham Biosciences, Piscataway, NJ, USA) was used for detection.

Evaluation of T-cell proliferation and activation. EV from either dnIKK2-Treg or Tact or Trest were added at day 0 of an allogeneic mixed leukocyte reaction (MLR) carried out with mature BN DC or WF (third party) DC as stimulators and LW lymph node (LN) cells as responders (1:100 ratio). Cultures were maintained in RPMI/FBS medium 20% in 5% CO₂ in air at 37 °C for 4 days. T cell proliferation was measured at 1, 3 and 4 days by adding 1 micro-Curie (µCi) [³H]-thymidine for the last 18 h, then the uptake of radioactivity was measured by liquid scintillation counting. Proliferation was expressed as counts per minute (cpm). In selected experiments,
dnIKK2-Treg-EV was added 30 min, 1, 2, 4, 6 and 24 h after the addition of the stimulators (either mature DCs or Concanavalin A, ConA, 5 μg/ml) and T cell proliferation was evaluated at the end of the 4-day stimulation. MLR experiments with LN cells obtained from long-term surviving rats were performed using as stimulators irradiated BN splenocytes. In additional experiments, T cell proliferation was evaluated by carboxyfluorescein-acetoxymethyl ester (CFSE) dilution method. Briefly, 10^6 LN cells were labeled with CFSE (Molecular Probe) and used as recipients and BN rats as donors. To test the immunomodulatory capacity of dnIKK2-Treg-EV, recipient rats were treated with dnIKK2-Treg-EV or vehicle and survival was monitored. Treatments with dnIKK2-Treg-EV depended in 0.2 ml PBS. Rats were given or not cyclosporine (CsA, 5 mg/Kg/day intramuscularly for 4 days; Novartis Farma, Milan, Italy) as specified. Renal function was monitored by evaluating serum creatinine levels using an auto-analyzer at 7, 14, 30 and 60 days post-transplant. Healthy animals that reached post-transplant day 60, were considered long-term surviving animals.

Statistical analysis. Results were given as mean ± standard error (SE) or standard deviation (SD) as stated. For all parameters, the significance of differences between individual groups was analyzed by one-way analysis of variance (ANOVA). Changes of the various parameters over time were evaluated by ANOVA for repeated measures. All data were analyzed using MedCalc 10.0.1 statistical software. Survival data were analyzed by the log-rank test. Statistical significance was defined as p < 0.05.

References
1. Lamb, K. E., Lodhi, S. & Meier-Kriesche, H. U. Long-term renal allograft survival in the United States: a critical reappraisal. Am. J. Transplant. 11, 450–62 (2011).
2. Sayegh, M. H. & Remuzzi, G. Clinical update: immunosuppression minimisation. Lancet. 369, 1676–8 (2007).
3. Morelli, A. E. & Thomson, A. W. Orchestration of transplantation tolerance by regulatory dendritic cell therapy or in-situ targeting of dendritic cells. Curr. Opin. Organ. Transplant. 19, 348–56 (2014).
4. Issa, F. & Wood, K. J. The potential role for regulatory T-cell therapy in vascularized composite allograft transplantation. *Curr. Opin. Organ. Transplant.* **19**, 558–65 (2014).
5. Ferrer, I. R., Hester, J., Bushell, A. & Wood, K. J. Induction of transplantation tolerance through regulatory cells: from mice to men. *Immunol. Rev.* **258**, 102–16 (2014).
6. Aiello, S. et al. DnKK2-transfected dendritic cells induce a novel population of inducible nitric oxide synthase-expressing CD4+CD25− cells with tolerogenic properties. *Transplantation* **83**, 474–84 (2007).
7. Tomasoni, S. et al. Dendritic cells genetically engineered with adenosine vector encoding dnKK2 induce the formation of potent CD4+ T-regulatory cells. *Transplantation* **79**, 1056–61 (2005).
8. Sakaguchi, S., Miyara, M., Costantino, C. M. & Hafler, D. A. FOXP3 regulatory T cells in the human immune system. *Nat. Rev. Immunol.* **10**, 490–500 (2010).
9. Bryniarski, K. et al. Antigen-specific, antibody-coated, exosome-like nanovesicles deliver suppressor T-cell microRNA-150 to effector T cells to inhibit contact sensitivity. *J. Allergy. Clin. Immunol.* **132**, 170–81 (2013).
10. Okaye, I. S. et al. MicroRNA-containing T-regulatory-cell-derived exosomes suppress pathogenic T helper 1 cells. *Immunity* **41**, 89–103 (2014).
11. Smyth, L. A. et al. CD73 expression on extracellular vesicles derived from CD4+CD25+ Foxp3+ T cells contributes to their regulatory function. *Eur. J. Immunol.* **43**, 2340–40 (2013).
12. Xie, Y., Zhang, X., Zhao, T., Li, W. & Xiang, J. Natural CD8+CD25+ regulatory T cells-secreted exosomes capable of suppressing cytotoxic T lymphocyte-mediated immunity against B16 melanoma. *Biochem. Biophys. Res. Commun.* **438**, 152–5 (2015).
13. Yu, X. et al. CD4+CD25+ regulatory T-cells-derived exosomes prolonged kidney allograft survival in a rat model. *Cell. Immunol.* **285**, 62–8 (2013).
14. Kowal, J., Tkach, M. & Thery, C. Biogenesis and secretion of exosomes. *Curr. Opin. Cell Biol.* **29**, 116–25 (2014).
15. Thery, C. Exosomes: secreted vesicles and intercellular communications. *F1000 Biol. Rep.* **3**, 15 (2011).
16. Tkach, M. & Thery, C. Communication by Extracellular Vesicles: Where We Are and Where We Need to Go. *Cell. 164*, 1226–32 (2016).
17. Liu, Q. et al. Donor dendritic cell-derived exosomes promote allograft-targeting immune response. *J. Clin. Invest.* **126**, 2805–20 (2016).
18. Marino, J. et al. Donor exosomes rather than passenger leukocytes initiate alloreactive T cell responses after transplantation. *Sci. Immunol.* **1**, eaaf7859 (2016).
19. Robbins, P. D. & Morelli, A. E. Regulation of immune responses by extracellular vesicles. *Nat. Rev. Immunol.* **14**, 195–208 (2014).
20. Li, X. et al. Tolerance induction by exosomes from immature dendritic cells and rapamycin in a mouse cardiac allograft model. *PLoS One.* **7**, e44045 (2012).
21. Peche, H. et al. Induction of tolerance by exosomes and short-term immunosuppression in a fully MHC-mismatched rat cardiac allograft model. *Am. J. Transplant.* **6**, 1541–50 (2006).
22. Lotvall, J. et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. *J. Extracell. Vesicles* **Collection** 2014, doi:10.3402/jev.v3.26913 (2014).
23. Witwer, K. W. et al. Standardization of sample collection, isolation and analysis methods in extracellular vesicle research. *J. Extracell. Vesicles* **Collection** 2013, doi:10.3402/jev.v2.20360 (2013).
24. Vlachos, I. S. et al. DIANA miPath v2.0: investigating the combinatorial effect of microRNAs in pathways. *Nucleic Acids. Res.* **40** (Web Server issue), W498–504 (2012).
25. Kaneshi, M., Furumichi, M., Tanabe, M., Sato, Y. & Morishima, K. KEGG: new perspectives on genomes, pathways, diseases and drugs. *Nucleic Acids Res.* **45**, D353–D361 (2017).
26. Kaneshi, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. *Nucleic Acids Res.* **44**, D457–D462 (2016).
27. Li, L. et al. Argonouute complex selectively protects the circulating microRNAs in cell-secreted microvesicles. *PLoS One.* **7**, e46957 (2012).
28. Watashi, K., Yeung, M. L., Starost, M. F., Hosmane, R. S. & Jeang, K. T. Identification of small molecules that suppress microRNA function and reverse tumorigenesis. *J. Biol. Chem.* **285**, 24707–16 (2010).
29. Noris, M. et al. Thymic microchimerism correlates with the outcome of tolerance-inducing protocols for solid organ transplantation. *J. Am. Soc. Nephrol.* **12**, 2815–26 (2001).
30. Burrell, B. E. et al. Tolerance and lymphoid organ structure and function. *Front. Immunol.* **2**, 64 (2011).
31. Larsen, C. P., Austyn, J. M. & Morris, P. J. The role of graft-derived dendritic leukocytes in the organization of vascularized allografts. Recent findings on the migration and function of dendritic leukocytes after transplantation. *Ann. Surg.* **212**, 308–15 (1990).
32. Parolini, I. et al. Microenvironmental pH is a key factor for exosome traffic in tumor cells. *J. Biol. Chem.* **284**, 34211–22 (2009).
33. Kosaka, N. et al. Secretory mechanisms and intercellular transfer of microRNAs in living cells. *J. Biol. Chem.* **285**, 17442–52 (2010).
34. Mittelbrunn, M. et al. Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells. *Nat. Commun.* **2**, 282, doi:10.1038/ncomms1285 (2011).
35. Fevrier, B. & Raposo, G. Exosomes: endosomal-derived vesicles shipping extracellular messages. *Curr. Opin. Cell Biol.* **16**, 415–21 (2004).
36. Montecalvo, A. et al. Mechanism of transfer of functional microRNAs between mouse dendritic cells via exosomes. *Blood.* **119**, 756–66 (2012).
37. Valadi, H. et al. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat.Cell Biol.* **9**, 654–9 (2007).
38. Forrest, A. R. et al. Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. *Leukemia.* **24**, 460–6 (2010).
39. Caporali, A. et al. Deregression of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. *Circulation.* **123**, 382–91 (2011).
40. Hirakawa, T. et al. miR-503, a microRNA epigenetically repressed in endometriosis, induces apoptosis and cell-cycle arrest and inhibits cell proliferation, angiogenesis, and contractility of human ovarian endometriotic stromal cells. *Human Reproduction.* **31**, 2587–2597 (2016).
41. Vodovotz, Y., Russell, D., Xie, Q. W., Bogdan, C. & Nathan, C. Vesicle membrane association of nitric oxide synthase in primary mouse macrophages. *J. Immunol.* **154**, 2914–25 (1995).
42. Bogdan, C. Nitric oxide and the immune response. *Nat. Immunol.* **2**, 907–16 (2001).
43. Hernansanz-Agustin, P. et al. Nitrosothiols in the immune system: signaling and protection. *Antioxid. Redox. Signal.* **18**, 288–308 (2013).
44. Tanner, F. C. et al. Nitric oxide modulates expression of cell cycle regulatory proteins: a cytostatic strategy for inhibition of human vascular smooth muscle cell proliferation. *Circulation.* **101**, 1982–9 (2000).
45. Pervin, S. et al. Nitric oxide-induced cytostasis and cell cycle arrest of a human breast cancer cell line (MDA-MB-231): potential role of cyclin D1. *Proc. Natl. Acad. Sci. USA.* **98**, 3583–8 (2001).
46. Ko, G. Y. & Kelly, P. T. Nitric oxide acts as a postsynaptic signaling molecule in calcium/calmodulin-induced synaptic potentiation in hippocampal CA1 pyramidal neurons. *J. Neurosci.* **19**, 6784–94 (1999).
53. Wang, D.
62. Aiello, S.
52. Anderson, P. & Gonzalez-Rey, E. Vasoactive intestinal peptide induces cell cycle arrest and regulatory functions in human T cells at multiple levels. Mol. Cell Biol. 30, 2537–51 (2010).
59. Wang, H. & Leigh, J. Effects of nitric oxide synthase inhibitor eNOS-2 on allograft survival in a rat heart transplantation model. J. Surg. Res. 190, 73–80 (2013).
61. Kumar-Roinè, S., Matsui, M., Chinain, M., Laurent, D. & Pauillac, S. Modulation of inducible nitric oxide synthase gene expression by vasoactive intestinal peptide in T cells. J. Clin. Immunol. 32, 677–84 (2012).
57. Crescitelli, R., Lasser, C., Szabo, T. G., Kittel, A. & Eldh, M. Distinct RNA profiles in subpopulations of extracellular vesicles: implications for T cell function. J. Extracell. Vesicles. 2, 1650039 (2013).
54. Wells, A. D. & Morawski, P. A. New roles for cyclin-dependent kinases in T cell biology: linking cell division and differentiation. Nat. Rev. Immunol. 14, 61–70 (2014).
60. Kanada, M. et al. Distinctive fates of biomolecules delivered to target cells via extracellular vesicles. Proc. Natl. Acad. Sci. USA 112, E1433–42 (2015).
56. Vishnubhatla, J., Corteling, R., Stevanato, R., Hicks, C. & Sinden, J. The development of stem cell-derived exosomes as a cell-free regenerative medicine. J. Circulat. Biomark. 3, doi:10.5772/58597 (2014).
58. Kanada, M. et al. Differential fates of biomolecules delivered to target cells via extracellular vesicles. Proc. Natl. Acad. Sci. USA 112, E1433–42 (2015).
59. Wang, H. & Leigh, J. Effects of nitric oxide synthase inhibitor ε-Nitro-L-Arginine methyl ester on silica-induced inflammatory reaction and apoptosis. Particle and Fibre Toxicology. 3, 14–23 (2006).
60. Grodziki, A. C. et al. A novel carbone derivative inhibits nitric oxide formation in macrophages independent of effects on tumor necrosis factor α and interleukin-1 mRNA expression. J Pharmacol Exp Ther. 352, 438–447 (2015).
55. Chunder, N., Wang, L., Chen, C., Hancock, W. W. & Wells, A. D. Cyclin-dependent kinase 2 controls peripheral immune tolerance. J. Clin. Immunol. 38, 5659–66 (2012).

Acknowledgements
This work was partially supported by Fondazione ART per la Ricerca sui Trapianti ONLUS (ART, Milano, Italy). SF, FR and FP are recipients of a fellowship from Fondazione ART per la Ricerca sui Trapianti. MB is a recipient of a fellowship from Fondazione ARMR Aiuti per la Ricerca sulle Malattie Rare (Bergamo, Italy). We thank Anna Pezzotta for her precious, expert technical assistance. The manuscript was proofread by Kerstin Mierke.

Author Contributions
S.A. and M.N. designed the study. S.A., F.R., M.N., S.T. and A.B. were responsible for interpretation of the data. S.A., F.R., E.P., L.C. and C.M. performed in-vitro experiments. L.L. performed miRNA profiling and real time PCR experiments. S.F. performed western blot analysis. M.T. performed FACS-sorting and FACS-analysis. N.A. and M.M. performed kidney transplant experiments and monitored serum creatinine. S.C. performed electron microscopy analysis. M.B. was responsible for miRNA target and pathway prediction analysis. S.A. together with A.B. wrote the paper. G.R. participated in discussion and critical revision of the manuscript.

Additional Information
Supplementary information accompanies this paper at doi:10.1038/s41598-017-08617-3

Competing Interests: The authors declare that they have no competing interests.

Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2017